Fulvestrant (Forschungskontext zur Krebschemoprävention — nur Untersuchung)
Deterministische Ansicht der Quelle YAML Entität. Klinische Autorität bleibt mit den zitierten Quell-IDs und Rezensenten Sign-off Zustand.
| ID | DRUG-FULVESTRANT-PREVENTION |
|---|---|
| Art | Arzneimittel |
| Aliase | FaslodexFulvestrant (Brustkrebschemoprävention)SERD chemoprevention research — fulvestrantФулвестрант (хіміопрофілактика раку молочної залози — лише дослідницький контекст) |
| Status | reviewed 2026-05-18 | pending_clinical_signoff |
| Erkrankungen | None declared |
| Quellen | SRC-NCCN-BREAST-2025 SRC-USPSTF-BREAST-2024 |
Drug Facts
| Klasse | Selektiver Östrogenrezeptorabbau (SERD) — Forschungs-nur Chemopräventionskontext |
|---|---|
| Verfahren | Pure estrogen-receptor antagonist that binds ER-α and induces its proteasomal degradation — no agonist activity in any tissue (true ER downregulator). Standard of care SECOND-LINE ENDOCRINE TREATMENT for HR+/HER2-negative metastatic breast cancer, especially after AI failure (paired with CDK4/6i, alpelisib, capivasertib). The chemoprev- ention RATIONALE is purely mechanistic — total ER blockade should theoretically prevent ER-driven carcinogenesis — but there is NO RCT-level primary-prevention evidence and the IM injection route plus toxicity profile preclude use in disease-free women. Listed here as a class-completeness entity for the SERD class only; engine MUST NOT surface for prevention. |
| Typische Dosierung | BEHANDLUNG (metastastischer HR+ Brustkrebs — für den Kontext): 500 mg IM an den Tagen 1, 15, 29, dann 500 mg I.I.M. monatlich. Zwei Injektionen 250 mg / 5 ml, eine in jedem Gesäßmuskel. CHEMOPREVENTION: Keine etablierte Dosis. NICHT empfohlen für Chemoprävention in jeder Richtlinie. Motor sollte nie Oberfläche dieses Medikament zur primären Prävention. |
| Ukraine registriert | Wahr |
| NSZU erstattet | Wahr |
| Ukraine zuletzt überprüft | 2026-05-18 |
Anmerkungen
STUB — v0.2 chemoprevention-workstream authoring (batch 3); pending two- Clinical-Co-Lead signoff per CHARTER §6.1 dev-mode. CLASS-COMPLETENESS entity for the SERD class — distinct from DRUG-FULVESTRANT (the treatment-context entity at drugs/fulvestrant.yaml). NO primary- prevention RCT exists for fulvestrant; the IM route + monthly clinic visit burden + toxicity profile preclude use in disease-free women. USPSTF 2024 (Grade B chemoprevention recommendation) and NCCN-Breast 2025 list tamoxifen, raloxifene, exemestane, anastrozole as chemoprevention options — NOT fulvestrant. Engine MUST NOT surface fulvestrant as a chemoprevention option. This entity exists only so SERD-class queries return a member; it is a research-only / discussion entity. Newer oral SERDs (elacestrant, giredestrant, camizestrant, imlunestrant) are in trials for treatment indications only and are also NOT prevention candidates as of 2026-05.
Verwendet von
Keine Rückverweise im YAML-Korpus gefunden.